Resolutions from the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 23 March 2017 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following were adopted:

Financial year 2016 and 2017

The Company's statutory Annual Report 2016. The actual remuneration of the Board of Directors for 2016 and the remuneration level for 2017. The final dividend for 2016 of DKK 4.60 for each Novo Nordisk A or B share of DKK 0.20. The total dividend for 2016 of DKK 7.60 includes both the interim dividend of DKK 3.00 for each Novo Nordisk A and B share of DKK 0.20 which were paid in August 2016 and a final dividend of DKK 4.60 for each Novo Nordisk A and B share of DKK 0.20 to be paid in March 2017.

Elections

Re-election of Göran Ando as chairman and Jeppe Christiansen as vice chairman of the Board of Directors. Re-election of Brian Daniels, Sylvie Grégoire, Liz Hewitt and Mary Szela as members of the Board of Directors. Election of Kasim Kutay and Helge Lund as new members of the Board of Directors. Re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as the Company's auditor.

Shares and capital

Reduction of the Company's B share capital by cancellation of part of the Company's own holding of B shares. The Company's B shares are reduced by DKK 10,000,000 from DKK 402,512,800 to DKK 392,512,800. The Company's A share capital of DKK 107,487,200 remains unchanged, whereby the Company's share capital will amount to DKK 500,000,000. Authorisation to the Board of Directors to increase the Company's share capital. Authorisation to the Board of Directors until the next Annual General Meeting to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital.

Other

Revised Remuneration Principles were adopted. Proposals from shareholders were not adopted.

Composition of the Board of Directors and its committees

After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.

The Board of Directors decided at the same time to establish a temporary Research & Development Committee in light of the recently updated research and development strategy and priorities. The Research & Development Committee will assist the Board of Directors with oversight of the research and development strategy, the pipeline and other tasks.

The Board of Directors, including its committees, are now composed as follows:

Göran Ando (chairman of the Board, of the Nomination Committee and of the Research & Development Committee) Jeppe Christiansen (vice chairman of the Board and chairman of the Remuneration Committee) Brian Daniels (member of the Research & Development Committee) Sylvie Grégoire (member of the Audit Committee and the Research & Development Committee) Liz Hewitt (chairman of the Audit Committee and member of the Nomination Committee) Liselotte Hyveled (employee representative and member of the Research & Development Committee) Kasim Kutay (member of the Nomination Committee and the Remuneration Committee) Anne Marie Kverneland (employee representative and member of the Remuneration Committee) Helge Lund (member of the Audit Committee and the Nomination Committee) Søren Thuesen Pedersen (employee representative and member of the Nomination Committee) Stig Strøbæk (employee representative and member of the Audit Committee) Mary Szela (member of the Remuneration Committee)

Further information

Company announcement No 20 / 2017 

PR170323_AGM_resolutions_UK


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

\Hugin